tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ERAS Stock Latest News

Alphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz
The FlyAlphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz
3d ago
F
M
Erasca double downgraded to Underperform at BofA
PremiumThe Fly
Erasca double downgraded to Underperform at BofA
3d ago
ERAS
Erasca downgraded to Underperform from Buy at BofA
PremiumThe Fly
Erasca downgraded to Underperform from Buy at BofA
3d ago
ERAS
Erasca downgraded to Equal Weight from Overweight at Morgan Stanley
PremiumThe Fly
Erasca downgraded to Equal Weight from Overweight at Morgan Stanley
20d ago
ERAS
Cautious Outlook on Erasca Due to Strategic Shifts and Delayed Clinical Data
PremiumRatings
Cautious Outlook on Erasca Due to Strategic Shifts and Delayed Clinical Data
20d ago
ERAS
Erasca’s Strategic Advancements in RAS Programs Justify Buy Rating
PremiumRatingsErasca’s Strategic Advancements in RAS Programs Justify Buy Rating
23d ago
ERAS
Erasca Reports Progress and Financial Stability in Q2 2025
Premium
Company Announcements
Erasca Reports Progress and Financial Stability in Q2 2025
25d ago
ERAS
Erasca files $500M mixed securities shelf
Premium
The Fly
Erasca files $500M mixed securities shelf
25d ago
ERAS
Erasca reports Q2 EPS (12c), consensus (12c)
PremiumThe Fly
Erasca reports Q2 EPS (12c), consensus (12c)
25d ago
ERAS
Erasca Confirms Directors and Ratifies KPMG Appointment
PremiumCompany Announcements
Erasca Confirms Directors and Ratifies KPMG Appointment
2M ago
8K
ERAS
Erasca announces IND clearance for ERAS-4001
PremiumThe Fly
Erasca announces IND clearance for ERAS-4001
3M ago
ERAS
Erasca price target lowered to $3 from $3.50 at Guggenheim
PremiumThe Fly
Erasca price target lowered to $3 from $3.50 at Guggenheim
4M ago
ERAS
Erasca’s Strategic Advancements and Promising RAS-Targeting Therapies Justify Buy Rating
PremiumRatingsErasca’s Strategic Advancements and Promising RAS-Targeting Therapies Justify Buy Rating
4M ago
ERAS
Erasca reports Q1 EPS (11c), consensus (13c)
Premium
The Fly
Erasca reports Q1 EPS (11c), consensus (13c)
4M ago
ERAS
Erasca announces IND clearance, prioritizing of RAS-targeting franchise
Premium
The Fly
Erasca announces IND clearance, prioritizing of RAS-targeting franchise
4M ago
ERAS
Erasca’s Innovative RAS/MAPK Pathway Targeting and Promising Preclinical Data Earns Buy Rating
PremiumRatings
Erasca’s Innovative RAS/MAPK Pathway Targeting and Promising Preclinical Data Earns Buy Rating
4M ago
ERAS
Erasca presents new RAS-targeting franchise data at AACR meeting
PremiumThe Fly
Erasca presents new RAS-targeting franchise data at AACR meeting
4M ago
ERAS
Erasca initiated with an Outperform at Raymond James
PremiumThe Fly
Erasca initiated with an Outperform at Raymond James
5M ago
ERAS
RVMD
Erasca’s Innovative RAS Platform: A Buy Rating for Potential Best-in-Class Therapeutics
PremiumRatings
Erasca’s Innovative RAS Platform: A Buy Rating for Potential Best-in-Class Therapeutics
6M ago
ERAS
Promising Clinical Developments and Strategic Acquisitions Drive Buy Rating for Naporafenib and Molecular Glue Assets
PremiumRatingsPromising Clinical Developments and Strategic Acquisitions Drive Buy Rating for Naporafenib and Molecular Glue Assets
6M ago
ERAS
Erasca, Inc. Reports 2024 Financial and Strategic Progress
Premium
Company Announcements
Erasca, Inc. Reports 2024 Financial and Strategic Progress
6M ago
ERAS
Erasca reports Q4 EPS (11c), consensus (13c)
Premium
The Fly
Erasca reports Q4 EPS (11c), consensus (13c)
6M ago
ERAS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >